Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Freenome logo — Outpacing cancer starts with early detection

Freenome

Outpacing cancer starts with early detection

Founded 2014 United States Brisbane, United States 403 employees Total: $1.14B Biotechnology, Pharmaceutical

General Information

Company Name Freenome
Founded Year 2014
Location United States Brisbane, United States
Founders / Decision Makers
Team member
Employees 403
Industries Biotechnology, Pharmaceutical
Business Model B2B, B2D, B2B2C
Revenue Model Service Fee, Performance Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Freenome. To contact Freenome, visit freenome.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Freenome compare?

A PDF of Freenome and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Freenome soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Freenome

Freenome, founded in 2014, is a rising star in the biotech sector headquartered in the United States. The company is dedicated to early cancer detection, aiming to empower individuals in the prevention, detection, and treatment of diseases. Their slogan, "Outpacing cancer starts with early detection," encapsulates their mission to develop next-generation blood tests through a combination of multiomics platforms and machine learning techniques.

Freenome's initial product focuses on detecting early-stage colorectal cancer and advanced adenomas, positioning them as pioneers in the field of preventive oncology. To date, they have successfully raised over $1.1 billion from esteemed investors such as Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis, and American Cancer Society’s BrightEdge Ventures.

The company recently secured a $75.00M late-stage VC investment from Roche in November 2025, underscoring investor confidence in their innovative approach and potential for significant impact in healthcare.

Business keywords: Biotech, Early Cancer Detection, Blood Tests, Multiomics, Colorectal Cancer, Advanced Adenomas, Non-invasive Testing, Disease Screening, Healthcare Innovation, Cancer Prevention, Cancer Treatment, Medical Technology, Patient Empowerment

Services & Products

Intelligent Screening Platform
Cancer Detection Tests
PREEMPT CRC Study
Blood-Based Diagnostics

Target Customers

Healthcare Professionals Medical Institutions Patients at Risk for Cancer Clinical Researchers

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC $75.00M 1
Roche
Roche
01 Nov 2025
Late VC $254.00M 19
ARTIS Ventures DCVC Polaris Partners
ARTIS Ventures, DCVC +17
01 Feb 2024
Series D $300.00M 29
ARTIS Ventures DCVC HBM Healthcare Investments
ARTIS Ventures, DCVC +27
01 Dec 2021
Series C $270.00M 22
DCVC Kaiser Permanente Ventures Polaris Partners
DCVC, Kaiser Permanente Ventures +20
01 Aug 2020
Series B $160.00M 8
Kaiser Permanente Ventures Polaris Partners RA Capital Management
Kaiser Permanente Ventures, Polaris Partners +6
01 Jul 2019
Series A $7.00M 10
Asset Management Ventures CRV Founders Fund
Asset Management Ventures, CRV +8
01 Aug 2017
Series A $65.00M 10
Asset Management Ventures CRV Founders Fund
Asset Management Ventures, CRV +8
01 Mar 2017
Seed $5.60M 4
Founders Fund DCVC Third Kind Venture Capital
Founders Fund, DCVC +2
01 Jun 2016
Seed Undisclosed 1
Loxbridge Research
01 Dec 2014

Latest News

View All
Freenome Appoints Linh H. Le as Chief Financial Officer — Biospace.com
Freenome Appoints Linh H. Le as Chief Financial Officer
Biospace.com Nov 23, 2025
FDA approved AI device that predicts cancer prognosis — Qz.com
FDA approved AI device that predicts cancer prognosis
Qz.com Nov 23, 2025
Freenome Appoints Industry Veteran Rob Guigley as Chief Commercial Officer to Drive Commercial Strat... — Fox2now.com
Freenome Appoints Industry Veteran Rob Guigley as Chief Commercial Officer to Drive Commercial Strategy, As Agreement with Exact Sciences Clears Antitrust Review
Fox2now.com Nov 10, 2025
7 Startups Transforming Digital Health in 2025 And Beyond — Netguru.com
7 Startups Transforming Digital Health in 2025 And Beyond
Netguru.com Sep 10, 2025
Exact Sciences at Baird Conference: Strategic Growth in Cancer Screening — Investing.com
Exact Sciences at Baird Conference: Strategic Growth in Cancer Screening
Investing.com Sep 09, 2025
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal? — Investors.com
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?
Investors.com Aug 07, 2025

Freenome Alternatives & Competitors

View All Alternatives
Freenome vs
Adela, Inc.
Adela, Inc. United States

Advancing the field of epigenomics to transform how cancer is detected and monitored.

70 employees
Biotechnology, Pharmaceutical
Compare Freenome vs Adela, Inc.
Freenome vs
Brenus Pharma
Brenus Pharma France

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣

Series A
21 employees
Biotechnology, Pharmaceutical
Compare Freenome vs Brenus Pharma
Freenome vs
dianosic
dianosic France

"Smartly designed for you"

Seed
13 employees
Biotechnology, Medical Devices
Also compare with: Freenome vs Amadix Amadix View all alternatives

FAQ About Freenome

Outpacing cancer starts with early detection
Freenome was founded in 2014.
Freenome is headquartered in Brisbane, United States.
Freenome operates in Biotechnology and Pharmaceutical. Its work centres on Biotech, Early Cancer Detection, Blood Tests and Multiomics. Its customers include Healthcare Professionals, Medical Institutions and Patients at Risk for Cancer.
Freenome has a B2B, B2D and B2B2C business model. Its revenue comes from Service Fee, Performance Based and Licensing.
Freenome has approximately 403 employees.
Freenome has completed 9 funding rounds, raising a total of $1.14B.
Freenome offers: Intelligent Screening Platform, Cancer Detection Tests, PREEMPT CRC Study, Blood-Based Diagnostics.
Top alternatives and competitors to Freenome include Adela, Inc., Brenus Pharma, dianosic, Yaqrit, Vivacitas Oncology Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Freenome and Adela, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Freenome, https://bouncewatch.com/company/freenome, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes